Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: